Masashi Kiyomine

We work to map the microbiome and illuminate interactions foundational to the health of humanity.

Beacons AI platform for brain data enables and accelerates new treatments that transform the lives of patients with neurological and psychiatric disease. Through FDA-cleared EEG wearables, novel machine learning algorithms, enormous datasets, and advances in software engineering, we are changing the way patients are treated for disorders of the brain. Want to join the team? We’re hiring—check out the careers page on our website for more. Please be advised that Beacon Biosignals does not ask for personal information outside of our official hiring process. If a role is not listed on our careers page, it is not an active job opening. We will never ask candidates to send money to supplement company equipment, and all official emails from our team will come from the @beacon.bio domain, never text messages or Teams messages.

Anise Health is a culturally-responsive digital mental health and wellbeing platform dedicated to meeting the unique needs of communities of color, starting with a focus on the Asian American population. We are founded by two minority female alumni of Harvard Business School and our clinical program is directed by Dr. Janie Hong, psychologist and Clinical Associate Professor at Stanford University School of Medicine. She is a founding partner at the Redwood Center for CBT and Research, where she maintains a small private practice. She also is the current chair of the Asian American in Behavior Therapy and Research Special Interest Group in the Association for Behavioral and Cognitive Therapies.

Jona is on a mission to reveal the relationship between our gut microbiome and health. Microbiome science has been exploding over the last decade with thousands of scientific studies showing the link to human health including GI conditions, autoimmune conditions, oncology, metabolic disease, athletic performance, longevity, depression, anxiety, Parkinson’s Disease and more. Yet, so far the microbiome has been too complex and the science too fast moving to benefit patients in practice. Jona has developed transformative AI technology to analyze an individuals microbiome, interpret the results, and summarize what is known today about that individuals microbiome profile based on the scientific literature. With actionable insights and recommendations, individuals can get to the root source of understanding their health, alleviate symptoms, and prevent chronic disease. We believe that fully realizing the microbiome in medicine will create whole new diagnostics, change patient pathways, develop new therapeutic classes, alter our food supply, and extend human longevity.

Started by Stanford/MIT serial entrepreneurs, Ruby Robotics is working to maximize patient outcomes with tissue insights at the point of care. Using custom-built hardware and AI, our platform is being developed with the goals of optimizing biopsy and surgical procedure workflow while delivering disease analytics early in the patient’s journey. Ruby Robotics was acquired in 2025 by Intuitive Surgical.

Digital Phenotyping for Mental Health. A revolutionary platform that assesses your mental state through personal device interactions. Always-On, Passive, and Accurate. Facebook uses digital behavior to analyze what you are going to buy next. Netflix evaluates digital behavior to identify what you are going to watch next. Behavidence analyses digital behavior to help manage your mental health.

Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development and validation of its pipeline of prescription-based digital therapies. Swing Therapeutics’ near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.

An evidence-based, AI-powered mental health support tool that helps your patients and members live well with symptoms of anxiety and depression. Interested in learning more about Woebot, the behavioral health copilot? Connect with us here: https://woebothealth.com/partner-with-us/ #mentalhealthawareness #mentalhealthmatters #mentalhealthadvocate #mentalhealth #woebothealth #behavioralhealth #digitaltransformation

On October 17, 2018, Oracle announced that it has signed an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials. goBaltos study startup solutions are activated at over 90,000 sites across 2,000+ studies in over 80 countries to deliver significant savings to customers with over 30 percent quantifiable reduction in study startup times. Today, Oracle Health Sciences offers customers the industrys most advanced cloud solution for clinical trial planning, data collection, trial execution and safety management. goBalto adds the leading industry cloud solution that significantly reduces clinical trial startup time. Together, Oracle and goBalto will provide the most complete end-to-end cloud platform dedicated to unifying action and accelerating results for the Life Sciences industry.

Symic Bio is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. While it is clear that cells play an important role in tissue inflammation and regeneration, it is also known that the extracellular matrix (ECM) plays an equally critical role in maintaining healthy tissue. The ECM is the non-cellular component of the body’s tissues, and proteoglycans are important structural and functional macromolecules native to the ECM that are known to protect against tissue degradation and promote healing during illness or injury. Recognizing the importance of proteoglycans in many acute and chronic disease states, Symic developed a library of proprietary, ECM-specific compounds that mimic the protective effect of natural proteoglycans. For controlled injuries (e.g. incisions, balloon angioplasty), Symic’s ECM-specific compounds allow for local application, enhancing their ability to attenuate inflammation and reduce scarring only at the site of injury. In disease states known for chronic inflammation involving the ECM (e.g. cartilage in osteoarthritis), Symic’s technology can disrupt the cycle of degradation-inflammation by directly targeting and protecting the injured ECM. The ECM plays a critical role in many acute and chronic disease states, many of which have limited or no effective therapeutic options. Symic plans to advance its compounds in a variety of therapeutic areas with unmet clinical needs.

MC10 reshapes electronics to create thin, conformal systems that flex, stretch, and bend seamlessly with the natural world. The company combines breakthrough technology with innovative engineering to develop products that advance quality of life. MC10 and its technology are now a part of Medidata Solutions Inc., a Dassault Systèmes company. Visit MC10 online at www.mc10inc.com and www.medidata.com/en/clinical-trial-products/patient-centric-clinical-trials

Change Healthcare is now a part of Optum. To stay up-to-date with news please connect with us at Optum.com. At both Optum and Change Healthcare, our teams strive to help people live healthier lives and help the health system work better for everyone.

EKOS Corporation, a BTG International group company, pioneered the development and clinical application of ultrasound infusion technologies in medicine. It introduced its first system for the treatment of vascular thrombosis (blood clots) in 2005. Since its beginning, EKOS has had one goal: develop life-enhancing and lifesaving treatments for blood clots that occur in arteries and veins. Our endovascular therapies improve patient outcomes, lower risks and improve treatment predictability.3,16,18 Today, interventional radiologists, cardiologists, vascular and cardiothoracic surgeons at leading institutions around the world use the EKOS EkoSonic® Endovascular System to provide faster, safer and more complete dissolution of thrombus.

Cardiovascular Systems, Inc. (CSI) is committed to providing innovative solutions for the revascularization of patients with complex coronary and peripheral artery disease (PAD). Our primary focus is helping physicians conquer even the most difficult disease states, including the challenge of arterial calcium for the millions who suffer from PAD and Complex PCI. CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe, effective, economical medical devices that improve patient outcomes. We are equally committed to creating an invigorating work environment for people who align with our Core Values of accountability, integrity, excellence, courage, velocity, and community. When each of our employees lives our Core Values, we’re doing everything we can to achieve our mission: Saving Limbs. Saving Lives. Every Day. It is the policy of CSI to provide equal employment opportunity (EEO) to all persons regardless of age, color, national origin, citizenship status, physical or mental disability, race, religion, creed, gender, sex, sexual orientation, gender identity and/or expression, genetic information, marital status, status with regard to public assistance, veteran status, or any other characteristic protected by federal, state or local law. In addition, CSI will provide reasonable accommodations for qualified individuals with disabilities. For more information, visit www.CSI360.com or connect with us on Twitter and Facebook. Read important safety information (https://csi360.com/indications-statements-important-safety-and-risk-information/).

We work to map the microbiome and illuminate interactions foundational to the health of humanity.

Beacons AI platform for brain data enables and accelerates new treatments that transform the lives of patients with neurological and psychiatric disease. Through FDA-cleared EEG wearables, novel machine learning algorithms, enormous datasets, and advances in software engineering, we are changing the way patients are treated for disorders of the brain. Want to join the team? We’re hiring—check out the careers page on our website for more. Please be advised that Beacon Biosignals does not ask for personal information outside of our official hiring process. If a role is not listed on our careers page, it is not an active job opening. We will never ask candidates to send money to supplement company equipment, and all official emails from our team will come from the @beacon.bio domain, never text messages or Teams messages.

Anise Health is a culturally-responsive digital mental health and wellbeing platform dedicated to meeting the unique needs of communities of color, starting with a focus on the Asian American population. We are founded by two minority female alumni of Harvard Business School and our clinical program is directed by Dr. Janie Hong, psychologist and Clinical Associate Professor at Stanford University School of Medicine. She is a founding partner at the Redwood Center for CBT and Research, where she maintains a small private practice. She also is the current chair of the Asian American in Behavior Therapy and Research Special Interest Group in the Association for Behavioral and Cognitive Therapies.

Jona is on a mission to reveal the relationship between our gut microbiome and health. Microbiome science has been exploding over the last decade with thousands of scientific studies showing the link to human health including GI conditions, autoimmune conditions, oncology, metabolic disease, athletic performance, longevity, depression, anxiety, Parkinson’s Disease and more. Yet, so far the microbiome has been too complex and the science too fast moving to benefit patients in practice. Jona has developed transformative AI technology to analyze an individuals microbiome, interpret the results, and summarize what is known today about that individuals microbiome profile based on the scientific literature. With actionable insights and recommendations, individuals can get to the root source of understanding their health, alleviate symptoms, and prevent chronic disease. We believe that fully realizing the microbiome in medicine will create whole new diagnostics, change patient pathways, develop new therapeutic classes, alter our food supply, and extend human longevity.

Started by Stanford/MIT serial entrepreneurs, Ruby Robotics is working to maximize patient outcomes with tissue insights at the point of care. Using custom-built hardware and AI, our platform is being developed with the goals of optimizing biopsy and surgical procedure workflow while delivering disease analytics early in the patient’s journey. Ruby Robotics was acquired in 2025 by Intuitive Surgical.